# US 2020/0399313 A1 · Compositions and methods for inhibiting cd279 interactions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0399313 A1
- Document ID: US20200399313A1
- Status: Published application
- Kind: A1
- Application number: 16/806,647
- Filed: 2020-03-02
- Published: 2020-12-24
- Earliest claimed: 2015-12-09
- Assignees: Virogin Biotech Canada Ltd
- Applicants: Virogin Biotech Canada Ltd.
- Inventors: William Jia; Xuexian Bu; I-Fang Lee
- Web page: https://patentgrep.com/patent/US20200399313A1

## CPC

- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- A61P 35/00: Antineoplastic agents
- C07K 14/70503: {Immunoglobulin superfamily}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 7/06: having 5 to 11 amino acids
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Methods and compositions for inhibiting and/or interfering with interactions between (1) programmed Death-1 protein (also known as CD279) and (2) programmed death-ligand 1 (PD-L1) and/or programmed death-ligand 2 (PD-L2) are disclosed. In addition, methods and compositions for increasing IL-2 levels in a cell, and methods and compositions for preventing, treating, or ameliorating the effects of cancer in a subject, are disclosed.

## Claims

### Claim at position 1

1-17. (canceled)

### Claim 18

An expression cassette, comprising control sequences operably linked to a sequence which encodes a peptide comprising one of SEQ ID NO:1-SEQ ID NO:36, linked to a fragment crystallizable (Fc) region of an antibody.

### Claim 19 (depends on 18)

The expression cassette according to claim 18, wherein said expression cassette encodes a peptide comprising SEQ ID NO: 2 linked to a fragment crystallizable (Fc) region of an antibody.

### Claim 20

A recombinant viral vector comprising an expression cassette that expresses a peptide comprising one of SEQ ID NO:1-SEQ ID NO:36, linked to a fragment crystallizable (Fc) region of an antibody.

### Claim 21 (depends on 20)

The recombinant viral vector according to claim 20 wherein said expression cassette expresses a peptide comprising SEQ ID NO: 2 linked to a fragment crystallizable (Fc) region of an antibody.

### Claim 22 (depends on 20)

The recombinant viral vector according to claim 20 wherein said viral vector is an HSV-1 vector.

### Claim 23 (depends on 20)

A method for producing a peptide in a subject, comprising introducing a vector according to claim 20 into said subject, such that said peptide is produced in said subject.

### Claim 24 (depends on 20)

A method for inhibiting interaction between PD-1 and PD-L1 in a cell by administering a recombinant viral vector according to claim 20 to the cell.

### Claim 25 (depends on 24)

The method according to claim 24, wherein the recombinant viral vector is formulated to be administered to a mammal via local tissue injection, intravenous injection or intraperitoneal injection.

### Claim 26 (depends on 20)

A method for treating cancer in a subject, comprising administering a recombinant viral vector according to claim 20 into a subject having a cancer, thereby treating said cancer.